Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study
Karol Mateusz Pencina et al. · The Journal of Clinical Endocrinology & Metabolism · 2023
Evidence type: Human randomized trialInterpretive weight: LimitedResearch area: NAD-related and cardiometabolic measures
DesignSingle-center, randomized, double-blind, placebo-controlled, parallel-group physiologic study; 28 days
PopulationOverweight or obese adults aged 45 years or older without diabetes
Sample30 randomized in a 2:1 ratio; 21 MIB-626 and 9 placebo
InterventionMIB-626 microcrystalline β-NMN 1,000 mg twice daily versus matching placebo for 28 days
EndpointsSafety and tolerability; Blood NAD+ and NAD metabolome; Body weight and body composition; Blood pressure and lipids; Insulin sensitivity; Liver and intra-abdominal fat; Muscle strength, fatigability, aerobic capacity and muscle bioenergetics
What the publication reported
This randomized trial tested a pharmaceutical formulation of NMN, MIB-626, at 2,000 mg/day for 28 days in 30 overweight or obese middle-aged and older adults.
MIB-626 substantially increased circulating NAD+ and related metabolites. The publication also reported greater reductions in body weight, diastolic blood pressure, total cholesterol, LDL cholesterol and non-HDL cholesterol than placebo.
Insulin sensitivity, liver and intra-abdominal fat, muscle strength, fatigability, aerobic capacity and stair-climbing power did not significantly improve. Because the study was small, short, and examined many outcomes without multiplicity adjustment, the cardiometabolic findings are exploratory.
Key findings
Circulating NAD+ and NAD-related metabolites increased substantially with MIB-626.
Adverse events were similar between treatment groups.
Body weight and several lipid measures decreased more in the MIB-626 group than placebo over 28 days.
Diastolic blood pressure decreased more in the MIB-626 group than placebo.
Insulin sensitivity, liver and intra-abdominal fat, and physical-performance endpoints did not significantly differ between groups.
The publication treated P values as nominal and did not adjust for multiple comparisons.
What it cannot establish
Small sample size of 30 participants.
Short 28-day intervention.
Many physiologic endpoints were assessed, and statistical comparisons were not adjusted for multiplicity.
The specific MIB-626 formulation is not automatically equivalent to other NMN products.
HealthspanX claim boundary: This record supports short-term NAD pharmacodynamics for MIB-626. It does not establish long-term cardiometabolic benefit, anti-aging or longevity effects, or equivalence with HealthspanX NMN.
